BioFuse is honored to announce the appointment of Dr. John Monson as Chief Medical Advisor!
MELBOURNE, FL / ACCESSWIRE / January 19, 2022 / BioFuse Medical Technologies, Inc., an emerging surgical device company with transformative tissue sealing and welding technology, today announced John Monson, MD as the company’s Chief Medical Advisor.
“This is a very exciting development for BioFuse,” said Gary Henley, president of BioFuse. “Dr. Monson is one of the top colorectal surgeons in the world, and we are thrilled to have him on board as the organization prepares for commercialization.”
Dr. Monson brings over three decades of experience with a skillset to help BioFuse in their go-to-market strategy, helping them navigate their clinical and commercial path to sales. Having served in leadership positions in major Academic Medical Centers on both sides of the Atlantic, he is currently the senior Colorectal Surgeon at AdventHealth Orlando, which is recognized by U.S. News & World Report as one of America’s best hospitals for gastroenterology and gastrointestinal surgery.
“I have dedicated three decades to becoming an expert in the care of patients with complex rectal cancer and inflammatory bowel disease like UC and Crohn’s Disease,” said Monson. “My passion has always been helping the patients with the most complex and difficult problems.”
“For all surgeons, anastomotic leaking is the most dreaded of complications and continues to be the leading cause of post-operative mortality after colorectal surgery. It’s time for a new approach to creating the safest anastomosis.”
Monson is credited with leading the development of laparoscopic colorectal surgery in the U.K., and he is a former chair of the U.K.’s National Training Program. He is Co-editor of several scientific journal and sit on numerous editorial boards. His research encompasses a broad range of cancer-related areas including the development of national standards, the development of new technologies in clinical care and qualitative assessments of decision-making in cancer care.
Monson chaired the AdventHealth program to achieve NAPRC accreditation for rectal cancer from the Commission on Cancer. Having given more than 1,000 lectures around the world, he has authored almost 400 original published papers, four books, and more than 250 book chapters.
To learn more about BioFuse Medical, visit biofusemedical.com
About BioFuse Medical Technologies, Inc.
BioFuse™ is a new RF tissue sealing and welding technology. Using transformative technology, proven in Europe in thousands of cases, this surgical innovation replaces traditional methods of sutures, staples, and electrosurgical vessel sealing. BioFuse technology can address a broad range of clinical applications, includes a robust pipeline of products in various stages of development, and has an FDA 510k clearance for vessel sealing, solid IP protection and trade secrets.
This technology will serve a large and growing target market of $3 billion. Market Data indicates a strong and growing demand for advanced, innovative devices that facilitate evolving surgical procedural techniques and vastly improve patient outcomes. Surgeons are looking for new solutions, the new technology that will eliminate scars and lower infection rates.
BioFuse is privately held and interested accredited investors may learn more about investment opportunities in the Company’s 506© offering by visiting: biofusemedical.com
SurgiFuse® is the core technology developed by BioFuse Medical Technologies. It is an advanced high-frequency electrosurgical system available and incorporates a unique and proprietary way of controlling and delivering energy to and through the target tissue. In studies, SurgiFuse® tissue fusion has been shown to be stronger than mechanical closure, creates a continuous seam in the tissue, and leaves no foreign bodies behind. SurgiFuse® encompasses the proprietary use of low voltages and high currents, optimized specifically for the tissue to be fused. In addition, energy output to the tissue occurs in pulses. These computer-controlled energy pulses create optimal temperatures that unravel large molecules in the tissue and as these molecules cool, they become intertwined and create a fusion. For more information on BioFuse please visit www.BioFuseMedical.com.
Gary Henley, President
BioFuse Medical Technologies, Inc.
BioFuse Medical Technologies, Inc.
6767 N. Wickham Rd., Suite 400, Melbourne, FL 32940